# Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

> **NCT00049036** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 106 (actual)

## Conditions studied

- AIDS-related Diffuse Large Cell Lymphoma
- AIDS-related Immunoblastic Large Cell Lymphoma
- AIDS-related Peripheral/Systemic Lymphoma
- AIDS-related Small Noncleaved Cell Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** etoposide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** vincristine sulfate
- **DRUG:** prednisone
- **DRUG:** cyclophosphamide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00049036
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2014-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049036, "Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00049036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*